Blog
RSS FeedPosted by Michael Wonder on 21 Nov 2023
ICER to assess treatment for chronic obstructive pulmonary disease
21 November 2023 - Report will be subject of Midwest England CEPAC meeting in June 2024; draft scoping document open ...
Posted by Michael Wonder on 14 Nov 2023
ICER publishes evidence report on treatment for pulmonary arterial hypertension
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
Posted by Michael Wonder on 01 Nov 2023
ICER to assess MDMA assisted therapy for post-traumatic stress disorder
1 November 2023 - Report will be subject of New England CEPAC meeting in May 2024; draft scoping document open ...
Posted by Michael Wonder on 02 Oct 2023
ICER publishes special report on Eliquis and Xarelto submitted to CMS as part of public comment process on Medicare drug price negotiations
2 October 2023 - Report tailored to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding ...
Posted by Michael Wonder on 27 Sep 2023
ICER appoints Daniel Ollendorf as Chief Scientific Officer and Director of HTA Methods and Engagement
27 September 2023 - Academic leader in HTA to rejoin ICER in November 2023. ...
Posted by Michael Wonder on 25 Sep 2023
ICER releases draft evidence report on treatment for pulmonary arterial hypertension
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...
Posted by Michael Wonder on 25 Sep 2023
ICER finalises 2023 updates to value assessment framework
25 September 2023 - Updates to methods and public meeting procedures reflect experience with previous framework, benchmarking with other HTA groups, ...
Posted by Michael Wonder on 11 Sep 2023
An alternative measure of health for value assessment: the equal value life-year
10 September 2023 - The quality-adjusted life-year (QALY) is an international standard in cost-effectiveness analysis. A known concern arises from the ...
Posted by Michael Wonder on 26 Jul 2023
ICER releases draft evidence report on treatment for metachromatic leukodystrophy
26 July 2023 - Registration now open for 3 August “Early Insights” webinar. ...
Posted by Michael Wonder on 25 Jul 2023
ICER to assess treatments for paroxysmal nocturnal haemoglobinuria
25 July 2023 - Report will be subject of CTAF meeting in February 2024; draft scoping document open to public ...
Posted by Michael Wonder on 05 Jul 2023
ICER to assess treatment for schizophrenia
5 July 2023 - Report will be subject of New England CEPAC meeting in February 2024; draft scoping document open ...
Posted by Michael Wonder on 21 Jun 2023
ICER receives grant from The Commonwealth Fund for annual assessment of coverage policies that present barriers to fair access
21 June 2023 - ICER’s third annual “Barriers to Fair Access” report will be published in November 2023. ...
Posted by Michael Wonder on 05 Jun 2023
ICER proposes updates to value assessment framework methods and procedures
5 June 2023 - Proposed updates reflect experience with current framework, benchmarking with other health technology assessment groups, and external stakeholder ...
Posted by Michael Wonder on 25 May 2023
ICER publishes final evidence report on treatments for non-alcoholic steatohepatitis
25 May 2023 - Independent appraisal committee narrowly voted that currently available evidence for resmetirom is adequate to demonstrate a net ...
Posted by Michael Wonder on 15 May 2023
ICER to assess treatment for pulmonary arterial hypertension
15 May 2023 - Report will be subject of Midwest CEPAC meeting in December 2023; draft scoping document open to ...